Shopping Cart
- Remove All
- Your shopping cart is currently empty
Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $55 | Backorder | |
5 mg | $256 | Backorder | |
10 mg | $483 | Backorder | |
25 mg | $1,130 | Backorder |
Description | Gastric inhibitory peptide (GIP) (22-51), a pro-atherogenic peptide comprised of 30 amino acids from the residues 22-51 of its precursor protein proGIP, is present in human plasma. It activates the degradation of IκB-α and the nuclear translocation of NF-κB in both macrophage-differentiated THP-1 cells and human aortic endothelial cells at a concentration of 1 µM. Additionally, in ApoE-/- mice, GIP (22-51) escalates the area of atherosclerotic lesions and plaque development in vivo. |
Alias | Glucose-dependent Insulinotropic Peptide (22-51), GIP (22-51) |
Molecular Weight | 3181.60 |
Formula | C140H226N44O41.XCF3COOH |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | H2O: Soluble |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.